Proteomics International supports fundraising efforts for Cancer Research by riding in the Sunsuper...
PromarkerD test scores show treatment with canagliflozin can lessen risk of diabetic kidney disease
Proteomics International in collaboration with Janssen Research & Development have shown that PromarkerD demonstrates the benefits of canagliflozin and offers potential as a precision diagnostic tool in diabetic kidney disease.
The latest research is published in the international peer-reviewed Journal of Clinical Medicine.